Testing a new prostate and kidney cancer drug with immunotherapy
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer (without “pure small-cell” prostate cancer) or metastatic clear-cell kidney cancer
- For prostate cancer: your PSA is at least 4, and it has gotten worse within the last 6 months
- You’ve had at least two prior cancer treatments that fit the trial rules (including specific hormone-blocking drugs for prostate cancer)
- For prostate cancer: you must have had PSMA-targeted radiotherapy (like 177Lu-PSMA-617) before joining (per the protocol)
- For clear-cell kidney cancer: your tumor must be clear-cell, measurable by scan, and you must have had prior PD-1/PD-L1 immunotherapy plus other treatment
- You can’t have had certain recent treatments or immune-related steroid use, and you must not have significant uncontrolled autoimmune or brain/nerve conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a combination of a radioactive drug that seeks out prostate cancer cells (Lutetium-177) with an immunotherapy (pembrolizumab). It is for men whose castration-resistant prostate cancer has spread and is no longer controlled by current hormone treatments.
This trial tests a new type of immune cell therapy (called AB-3028) designed to recognize and attack prostate cancer cells that have the PSMA protein on their surface. It's for people whose prostate cancer has spread and is no longer controlled by hormone therapy.
Hear when a new Metastatic Castration-Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.